Finasteride Tablets

This drug belongs to the 4-nitrogen steroid hormone compound and is a specific type II 5alpha;-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the levels of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia by reducing the levels of dihydrotestosterone in the blood and prostate tissues, and improves the related clinical symptoms of benign prostatic hyperplasia.

Each tablet contains 5 mg of finasteride.

Finasteride Tablets: This product is a special-shaped film-coated tablet, which is white or off-white after removing the coating. Tamsulosin Hydrochloride Sustained Release Capsules: This product is a capsule, and the contents are off-white spherical particles.

This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH): 1. Improve symptoms. 2. Reduce the risk of acute urinary retention. 3. Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.

Oral. Recommended dose: 5 mg (1 tablet) once a day, either on an empty stomach or with food.

This product is generally well tolerated, and adverse reactions are usually mild, so it is generally not necessary to discontinue treatment. The safety of finasteride in the treatment of alopecia was evaluated in a series of clinical studies involving more than 3,200 male patients. In three 12-month, placebo-controlled, double-blind studies involving multiple research centers, the safety of this product was similar to that of placebo. 1.7% of the 945 male patients treated with this product discontinued treatment due to adverse reactions, while 2.1% of the 934 male patients treated with placebo discontinued treatment due to adverse reactions. In these studies, ge;1% of male patients treated with this product experienced the following medication-related adverse reactions: decreased libido (1.8% for this product, 1.3% for placebo) and impotence.

This product is contraindicated for use in pregnant women or women who may become pregnant (see [Use in Pregnant and Lactating Women]). This product is not suitable for women and children if you are allergic to any ingredient in this product.

Precautions for children: This product is not suitable for children. Precautions for pregnancy and lactation: This product is contraindicated for women who are pregnant or may become pregnant. Precautions for the elderly: See the specific description in [Usage and Dosage].

No clinically significant drug interactions have been identified. 1. Finasteride has no significant effect on the cytochrome P450-related drug metabolizing enzyme system. Compounds that have been tested in men include propranolol, digoxin, glibenclamide, warfarin, theophylline, and antipyrine, none of which have been found to have clinically significant interactions with finasteride. 2. Other combined therapies. Although no specific drug interaction studies have been conducted, in clinical studies, no significant clinical adverse interactions were found when finasteride was used simultaneously with angiotensin-converting enzyme inhibitors, acetaminophen, acetylsalicylic acid, alpha-blockers, beta-blockers, calcium channel blockers, nitrates for heart disease, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones, and benzodiazepines.

Keep in a dark, airtight, cool and dry place.

5 mg

24 months